# Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)

> **NCT07347197** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Heartseed Inc.** · enrollment: 14 (estimated)

## Conditions studied

- Heart Failure
- Ischemic Heart Failure
- Ischemic Heart Disease
- Dilated Cardiomyopathy (DCM)

## Interventions

- **COMBINATION_PRODUCT:** HS-005

## Key facts

- **NCT ID:** NCT07347197
- **Lead sponsor:** Heartseed Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2030-01-31
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07347197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07347197, "Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07347197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*